JOIN THE DEBATE!

Share your questions and comments with us throughout the day.

WIFI password: scotland

#newdeal4meds

Co-funded by
The health Programme of the European Union

The European Public Health Alliance has received funding under an operating grant from the European Union’s Health Programme (2014-2020). The content of this publication represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.
The past three editions of the Forum have consistently continued to change the way we talk about pharmaceutical policies in Brussels. The European Public Health Alliance (EPHA) access to medicines advocacy has raised the bar on the debate and succeeded in introducing a new, meaningful and genuine dialogue on all of the issues around pharmaceutical and medicines policies on the agenda in Brussels and beyond.

With “Healthy Innovation for All”, the first edition of our Forum in 2016, EPHA partnered with the Polish Government, the first time a civil society organization joined forces with an EU Member State to put all of the issues concerning pharmaceutical companies and medicines policies on the agenda.

The first Forum took place a few months after the groundbreaking June Council Conclusions on pharmaceutical systems in the EU and the Member States, the culmination of the disruptive EU Dutch Presidency. After this point, the public discourse around pharmaceuticals would never be the same again. EU Health Ministers made it clear that the current pharmaceutical business model was no longer sustainable and should be reviewed. The Conclusions were only the beginning, coinciding with a series of unprecedented political developments at national, European and global level.

We have come a long way in a very short period of time. The fourth edition of the Forum, titled “Time for a New Deal: Challenging the status quo on medicines policy,” seeks to set the scene and tone for the new European Commission and Parliament.
There is now broad political consensus that there are a series of imbalances in the pharmaceutical systems which need to be fixed in order to guarantee better and affordable medicines for patients.

“EU plans around cancer: Hype VS substance”, “Norway’s views on access to medicines”, “An old new problem: Solutions to medicines shortages in Europe”, “Pharmaceuticals, a secretive business: How to shed light into the black box?” are the themes for discussion at this year’s Forum guided by the priorities of EPHA members and the current policy agenda.

Many of the speakers are EPHA members. This is testament to the fact that EPHA and our members have been centre stage in influencing the agenda, forging new coalitions, highlighting the public health perspective and ensuring a more inclusive and balanced discussion around medicines policy.

Thank you once again for taking part and adding your voice to the debate. We wish you an enjoyable and interesting day discussing a #newdeal4meds.
ABOUT EPHA’S UNIVERSAL ACCESS AND AFFORDABLE MEDICINES ADVOCACY

EPHA’s Universal Access and Affordable Medicines advocacy promotes transparency, accountability and the public interest in the field of pharmaceuticals in line with the priorities of our members most active in this field. We aim to guarantee better and affordable medicines for Europe by questioning and calling for reforms to the current pharmaceutical business model to ensure better access to medicines for all.

Developed in response to the growing risk to patients and healthcare systems from the increasing costs of medicines, our advocacy is driven by our members’ interests, complimenting their work at local, national and European level. Through regular meetings, working groups and conferences, we exchange views with other stakeholders and develop positions, often in common, on key aspects of medicines policy, a small sample of which you can find at the end of this programme.

EPHA collaborates with several governments in Europe to drive the access to medicines debate forward and to ensure that all voices, including those of patients, are heard. As the only representative of expert civil society, in May 2017, EPHA took part in the third round-table discussion between Health Ministers and European heads of pharmaceutical companies in Valletta, Malta. EPHA is now a member of the High-Level Group mandated by the Health Ministers to prepare the agenda for the annual round-table discussions.
“Healthy Innovation for All”, the EPHA 2016 Universal Access and Affordable Medicines Forum (November 2016) was the first ever pharma-related, civil society event to take place under the auspices of an EU Member State (Poland). The second forum, the following year, “Game Changers for better and affordable medicines for Europe”, under the auspices of the incoming Bulgarian Presidency of the EU provided input to the Presidency’s work by fostering an honest discussion around the hottest topics in pharmaceutical policy.

EPHA also contributes to the debate at global level, partnering in June 2017 with the Collaboration for Research Integrity and Transparency (CRIT) of Yale University to co-host an international conference in New Haven, Connecticut titled “Ensuring Safety, Efficacy, and Access to Medical Products in the Age of Global Deregulation.” EPHA is regularly invited by the Organisation for Economic Cooperation and Development (OECD) and the World Health Organization (WHO) to contribute to ongoing access to medicines policy debates.

EPHA’s members view Health Technology Assessment (HTA) as a powerful ally of patients and health care systems. As one of the members of the HTA Stakeholder Pool, EPHA helps to shape the future of European collaboration in the field of HTA, publishing our recommendations to improve the European Commission’s proposal in July this year. Committed to supporting the work of the European Medicines Agency (EMA) and defending its independence, EPHA’s recommendations calling for more transparent scientific advice by the EMA to the pharmaceutical sector, are endorsed by numerous organisations including two national Health Technology Assessment Agencies (KCE and LBI-HTA) and by the Belgian Social Insurance Agency (RIZIV/INAMI). EPHA also actively participates in the Patient and Consumer Working Party (PCWP) of the EMA.

In May 2019, EPHA’s Policy Manager for Universal Access and Affordable Medicines, Yannis Natsis was appointed by EU Member States to the EMA’s Management Board as a patient representative with a 3-year mandate, recognition of EPHA’s credibility and strong access to medicines advocacy.
EPHA is a long-standing partner of the European Health Forum Gastein (EHFG), joining forces with Open Society Foundations and the European Alliance for Responsible R&D and Affordable Medicines in 2018 and the European Public Health Association (EUPHA) in 2016 and 2017 to organize agenda-setting sessions on different aspects of the access to medicines debate.

Finally, EPHA is a founding member and hosts the secretariat of the European Alliance for Responsible R&D and Affordable Medicines, an informal coalition of more than 80 European and national organisations working exclusively on access to medicines issues.
09:00-09:30  REGISTRATION AND COFFEE

09:30-09:45  WELCOME AND INTRODUCTION
  • Fiona Godfrey, Secretary General, European Public Health Alliance (EPHA)
    @fjgodfrey @EPHA_EU

09:45-11:15  EU PLANS AROUND CANCER: HYPE VS SUBSTANCE
  Open discussion moderated by Rohit Malpani, Board Member, UNITAID
  • Denis Lacombe, Director-General, European Organisation for Research and Treatment of Cancer (EORTC)
    @EORTC
  • Kathi Apostolidis, President, European Cancer Patient Coalition (ECPC)
    @cancereu @kgapo
  • Carin Uyl-de Groot, Professor, Health Technology Assessment, Director of the Institute for Medical Technology Assessment (iMTA), School of Health Policy & Management, Erasmus University Rotterdam
    @ESHPM_EUR
  • Ward Rommel, Researcher, Kom op tegen Kanker, Access to Medicines Task-Force, European Cancer Leagues (ECL)
    @CancerLeagues @KOTKanker @WardRommel
  • Chantal Bélorgey, Head, Health Technology Assessment (HTA) and Public Health division, French Health Authority (Haute Autorité de Santé - HAS)
    @HAS_sante

11:10-11:30  COFFEE BREAK

11:30-12:00  ACCESS TO MEDICINES – HIGH AND UNSUSTAINABLE PRICE LEVELS: KEYNOTE
  • Bjørn-Inge Larsen, Secretary-General, Ministry of Health and Care Services, Norway
    @helse_og_omsorg
  • Yannis Natsis, Policy Manager, Universal Access and Affordable Medicines, EPHA Member, Management Board, European Medicines Agency
    @ynatsis @EPHA_EU

12:00-13:00  LUNCH
**4th EPHA Universal Access and Affordable Medicines Forum**

**Time for a New Deal: Challenging the status quo on medicines policy**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:25</td>
<td>AN OLD NEW PROBLEM: SOLUTIONS TO MEDICINES SHORTAGES IN EUROPE</td>
<td>Open discussion moderated by Rohit Malpani, Board Member, UNITAID</td>
</tr>
</tbody>
</table>
|               |                                                                                |  • Vlad Mixich, Coordinator, Romanian Health Observatory – Board member, EPHA  
|               |                                                                                |   @mixich                                                                |
|               |                                                                                |  • Charlotte Roffiaen, EU Advocacy Advisor, France Assos Santé (FAS)      |
|               |                                                                                |   @Fr_Assos_Sante @EU4Ublog                                               |
|               |                                                                                |  • Aida Batista, Vice-President, European Association of Hospital Pharmacists (EAHP)  |
|               |                                                                                |   @EAHPtweet @AidaBatista                                                 |
|               |                                                                                |  • Kasper Ernest, Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC)  |
|               |                                                                                |   @EAEPC_Brussels @KasperErnest                                          |
| 14:25-14:45   | COFFEE BREAK                                                                  |                                                                         |
| 14:45-16:15   | PHARMACEUTICALS, A SECRETIVE BUSINESS: HOW TO SHED LIGHT INTO THE BLACK BOX? | Open discussion moderated by Rohit Malpani, Board Member, UNITAID       |
|               |                                                                                |  • Audun Hågå, Head, Norwegian Medicines Agency                           |
|               |                                                                                |   @Legemiddelinfo                                                        |
|               |                                                                                |  • Alexander Roediger, Executive Director Oncology Policy, Europe, Middle East, Africa and Canada (EMEAC), MSD International  |
|               |                                                                                |   @MSDInvents                                                            |
|               |                                                                                |  • Marcel van Raaij, Director, Pharmaceutical Affairs and Medical Technology, Ministry of Health, Welfare and Sports, The Netherlands  |
|               |                                                                                |   @MinVWS @MarcelvanRaaij                                                |
|               |                                                                                |  • Fergal O’ Regan, Head of Enquiries, European Ombudsman                 |
|               |                                                                                |   @EUombudsman                                                           |
|               |                                                                                |  • Ellen t’ Hoen LLM, PhD, Medicines Law & Policy                       |
|               |                                                                                |   @MedsLawPolicy @ellenthoen                                              |
| 16:15-16:30   | CLOSING REMARKS                                                               |                                                                         |
| 16:30-17:30   | NETWORKING RECEPTION                                                          |                                                                         |
WELCOME AND INTRODUCTION

09:30–09:45

**Rohit Malpani**

Board Member, UNITAID

Rohit Malpani is currently a Board Member for Unitaid and a consultant focusing upon innovation and access to medicines, antimicrobial resistance, and the ethics and governance of artificial intelligence in health care. Previously Director of Policy and Advocacy for Médecins Sans Frontières Access Campaign, he has also served as a Special Advisor to Oxfam. Mr Malpani has also worked as an advisor to the WHO on health and human rights and as a lawyer at the law firm of Wilson Sonsini in Silicon Valley. He is currently based in Paris.

**Fiona Godfrey**

Secretary General, European Public Health Alliance (EPHA)

@fjgodfrey @EPHA_EU

Fiona Godfrey was appointed Secretary General of the European Public Health Alliance (EPHA) in January 2019. She has nearly two decades of experience in public health advocacy, from her first role as the EU Policy Director for the European Respiratory Society (2000–2008), to her most recent position as Director of Public Affairs at the European Association for the Study of the Liver (2013–2018). Currently, she is also Co-Chair of British in Europe and a member of the European Commission’s Mission Board for Cancer.
EU PLANS AROUND CANCER: HYPE VS SUBSTANCE

09:45-11:10

Denis Lacombe
Director-General, European Organisation for Research and Treatment of Cancer (EORTC)
@EORTC

Dr. Lacombe was appointed Director-General of the European Organisation for Research and Treatment of Cancer (EORTC) in 2015. He joined the EORTC in 1993, and was involved, among others, in the conduct of clinical research. Before this, Dr. Lacombe worked as a clinical research advisor. He holds a medical degree from the University of Marseilles, a fellowship in pharmacology and pharmacokinetics at the Roswell Park Cancer Institute in Buffalo, and has authored over 100 peer-reviewed publications.

Kathi Apostolidis
President, European Cancer Patient Coalition (ECPC)
@cancereu @kgapo

President of the European Cancer Patient Coalition (ECPC) and the Hellenic Cancer Federation (ELLOK), cancer survivor and patient advocate, Kathi Apostolidis advocates at national and international level for affordable, state-of-the-art cancer care, new therapies and research, patient empowerment and involvement and patient rights. As well as representing the ECPC at the Patients and Consumers Working Group of the European Medicines Agency and at the EU Joint Action on Cancer Control (CanCon), Ms Apostolidis is also a member of, amongst others, the European Commission Expert Group on Cancer Control.
Carin Uyl-de Groot
Professor, Health Technology Assessment, Director, Institute for Medical Technology Assessment (iMTA), School of Health Policy & Management, Erasmus University Rotterdam, Member, European Hematology Association (EHA) Task Force on Fair Pricing
@ESHPM_EUR

Carin Uyl-de Groot is Professor of Health Technology Assessment (HTA) at the Erasmus University Rotterdam. She is Head of the HTA Section of the Erasmus School of Health Policy & Management and Director of the Institute for Medical Technology Assessment (iMTA b.v.). Her research activities are mainly focused on cost-effectiveness and outcomes studies in cancer. In 2018, Prof Uyl-de Groot was Chair of the public health and health economics track of the ESMO 2018 conference. Prof. Uyl-de Groot is a member of the European Hematology Association (EHA) Task Force on Fair Pricing.

Ward Rommel
Researcher, Kom op tegen Kanker, Access to Medicines Task-Force, European Cancer Leagues (ECL)
@CancerLeagues @KOTKanker @WardRommel

Ward Rommel is the Interim Chair of the Access to Medicines Task Force of the Association of European Cancer Leagues (ECL) on behalf of Kom op tegen Kanker, the Belgian Foundation against Cancer. Mr Rommel joined Kom op tegen Kanker in 2004, and has consistently been active on the affordability of cancer treatment.
Chantal Bélorgey
Head, Health Technology Assessment (HTA) and Public Health division, French Health Authority (Haute Autorité de Santé - HAS)
@HAS_sante

Chantal Bélorgey, MD, PhD, is the Head of the Health Technology Assessment and Public Health division at the French Health Authority, responsible for providing scientific expertise for health technologies reimbursement and price decisions. Previously, Ms Bélorgey led the Department of Medicines, Clinical Practice Recommendations, and Quality of Expertise at the French National Cancer Institute (INCa) and was Counsellor for the French Minister of Health between 2012–2014.
ACCESS TO MEDICINES – HIGH AND UNSUSTAINABLE PRICE LEVELS

KEYNOTE & BRIEF EXCHANGE WITH BJØRN-INGE LARSEN
MODERATED BY YANNIS NATSIS

11:30-12:00

Bjørn–Inge Larsen
Secretary-General, Ministry of Health and Care Services, Norway
@helse_og_omsorg

Bjørn–Inge Larsen became Permanent Under-Secretary of State in the Ministry of Health and Care Services in October 2012. Previously, Mr Larsen held the post of Director of the Norwegian Directorate for Health and Social Affairs. He was a member of the Executive Board of WHO for the period 2010 to 2013, and holds a degree in medicine from the University of Oslo and a MBA and Masters in Public Health from the University of California, Berkeley.

Yannis Natsis
Policy Manager, Universal Access and Affordable Medicines, EPHA
Management Board Member, European Medicines Agency (EMA)
@ynatsis @EPHA_EU

Yannis Natsis leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Previously, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the United Nations and the private sector in Brussels and Athens. Between 2013–2015, Mr Natsis was Advocacy Advisor for the Trans-Atlantic Consumer Dialogue (TACD), and worked as a journalist between 2006–2010. In May 2019, he was appointed to the Management Board of the European Medicines Agency (EMA) by EU Member States. Mr Natsis also sits on the Board of the European Health Forum Gastein (EHFG).
AN OLD NEW PROBLEM: SOLUTIONS TO THE MEDICINES SHORTAGES IN EUROPE

13:00-14:25

Vlad Mixich
Coordinator, Romanian Health Observatory – Board member, European Public Health Alliance (EPHA) @mixich

Vlad Mixich is Executive Director of the Romanian Health Observatory and since July 2019, Board Member of the European Public Health Alliance. A trained medical doctor with a Masters degree from the London School of Economics and Political Science, he works as a health policy expert for international organisations. Active in health policy strengthening in Central And Eastern Europe, he has been Vice-President of the National Agency for Medicines and Medical Devices and a Counsellor to the Minister of Health between 2015 and 2017. More recently, he was a Humphrey Fellow at Rollins School of Public Health (Emory University, US), where he was engaged in research and teaching.

Charlotte Roffiaen
EU Advocacy Advisor, France Assos Santé (FAS) @Fr_Assos_Sante @EU4Ublog

Charlotte Roffiaen has been involved in advocacy since 2001, when she contributed to the creation and the development of Active Citizenship Network. A trained lawyer, Ms Roffiaen now advises CSOs on their European strategy in the health field, chiefly representing France Assos Santé, a French non-profit organisation with over 80 member associations) advocating for patients and health care users’ rights. She has a special interest in EU policy on medicines, with a focus on shortage management. Ms Roffiaen was a member of the ESMO Patients Advocates Working Group from 2017 to 2019.
Aida Batista

Vice-President, European Association of Hospital Pharmacists (EAHP)
@EAHPTweet @AidaBatista

Aida Batista is Vice-President of the European Association of Hospital Pharmacists (EAHP). She works as a Hospital Pharmacist Specialist within the organisation, previously holding the position of Director of Pharmacy Department at Centro Hospitalar Vila Nova de Gaia (CHVNG/E, EPE), Portugal. Her key areas of interest are management, procurement and medicines shortages.

Kasper Ernest

Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC) @EAEPC_Brussels @KasperErnest

Kasper Ernest has been Secretary-General of the European Association of Euro-Pharmaceutical Companies (EAEPC) since 2018, having previously been Director of the EU & International Department of the Confederation of Danish Enterprise. He has also served as Board Member of several EU-level business organisations, as a Member of the Danish Government’s Implementation Council, and was co-founder of the European Business Services Alliance. He holds a Masters degree in International Business and Politics of Science from Singapore Management University and Copenhagen Business School, where he is currently an external lecturer.
PHARMACEUTICALS, A SECRETIVE BUSINESS: HOW TO SHED LIGHT INTO THE BLACK BOX?

14:45–16:15

**Audun Hågå**

Head, Norwegian Medicines Agency

@Legemiddelinfo

Audun Hågå was appointed Director General of the Norwegian Medicines Agency in 2013. Previously, Mr Hågå was Deputy Director General at the Norwegian Ministry of Health and Care Services for ten years. He held the position of Head of Department at the Norwegian Medicines Agency with pricing and reimbursement for 6 years. Prior to his experience as a civil servant, Mr Hågå worked in the pharmaceutical industry for 10 years, based both in Norway and Sweden. He holds a Candidatus scientiarum degree from the University of Oslo (Norway) in Biology (Zoo-physiology).

**Marcel van Raaij**

Director, Pharmaceutical Affairs and Medical Technology, Ministry of Health, Welfare and Sports, The Netherlands

@MarcelvanRaaij @MinVWS

Marcel van Raaij is the Director of the Pharmaceutical Affairs and Medical Technology, Ministry of Health, Welfare, and Sports of The Netherlands. Previously, he led the Center for Integrated Risk Assessment and was appointed Acting Director for Nutrition, Medicines and Consumer Safety and Director of Environment and Safety at the National Institute of Public Health and Environment (RIVM). He contributed to several international working groups and commissions at EU, WHO and OECD level. Mr van Raaij studied Medical Biology and received his PhD in Physiology at the State University of Leiden.
Fergal O’Regan
Head of Enquiries, European Ombudsman @EUombudsman

Fergal O’Regan is Head of Inquiry Coordination at the European Ombudsman. He has been praised for playing a key role in modernising and increasing the effectiveness of the procedures of the Ombudsman. Before his appointment at the European Ombudsman, he worked as a lawyer specialising in EU competition law. Currently a Visiting Professor at the College of Europe, Bruges, Mr O’Regan holds a Masters Degree in European Law from the College of Europe and law degrees from the Université d’Aix-Marseille and the Universidad de Deusto, Bilbao.

Ellen t’ Hoen LLM, PhD
Medicines Law & Policy @MedsLawPolicy @ellenthoen

Ellen ‘t Hoen, LLM PhD, is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies at Medicines Law & Policy. She is currently a researcher at the Global Health Unit of the University Medical Centre at the University of Groningen. Ms ‘t Hoen was the Director of Policy for Médecins sans Frontières’ Campaign for Access to Essential Medicines (1999–2009), and worked with UNITAID in Geneva to set up the Medicines Patent Pool (MPP).
Alexander Roediger
Executive Director Oncology Policy, Europe, Middle East, Africa and Canada (EMEAC), MSD International @MSDInvents

Alexander Roediger leads Oncology Policy at MSD for Europe, Middle East, Africa and Canada (EMEAC), focusing on health system financing, pricing and reimbursement and innovation policies. He is currently Chair of the EFPIA Oncology Steering Committee and Chair of the Healthcare Committee of the American Chamber of Commerce to the EU. Previously, he worked for UNICEF Switzerland and Helsana Insurances. He has a Master’s degree in Philosophy from the University of Zurich and an Executive Master’s Degree in Business Administration from the University of St. Gallen.
ACCESS TO MEDICINES RESOURCES BY EPHA AND ITS MEMBERS

EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS (EAHP)
EAHP’s 2018 Survey on Medicines Shortages to improve patient outcomes,
Position paper on Medicines Shortages,
Position paper on Procurement,

EUROPEAN AIDS TREATMENT GROUP (EATG)
Position paper on ensuring affordable anti-retroviral drugs, sustainable universal access to treatment, as well as continued innovation in research and development,

EUROPEAN CANCER LEAGUES (ECL)
WHO Resolution: What’s Next on Transparency - Position Paper
EMA Regulatory Science 2025 - Submission to a public consultation
Let’s Talk Access - White Paper on Tackling Challenges in Access to Medicines
https://www.europeancancerleagues.org/lets-talk-access/
CAR-T Cell Therapies: How much for survival? - Analysis
European Cooperation on Health Technology Assessment (HTA) - Position Paper

EUROPEAN CANCER ORGANISATION (ECCO)
Access to Innovation, https://www.ecco-org.eu/Policy/Policy-Priorities/Access-to-Innovation

EUROPEAN PUBLIC HEALTH ALLIANCE (EPHA)
Response to public consultation on EMA Regulatory Science to 2025
Getting it right - EPHA recommendations on the improvement of the European
Commission proposal on Health Technology Assessment (HTA),
https://epha.org/epha-recommendations-ec-health-technology-assessment-hta/
EPHA recommendations on a new model for the provision of Scientific Advice,
https://epha.org/recommendations-on-a-new-model-for-the-provision-of-scientific-advice/
Reflection Paper | BENELUXA: First results of multi-country cooperation on medicine price negotiations,
https://epha.org/discussion-paper-beneluxa
EPHA Briefing | Will fast-tracking medicines improve affordability?
Scientists voice concerns about adaptive pathways,
https://epha.org/scientists-voice-concerns-about-adaptive-pathways/

FRANCE ASSOS SANTÉ
Médicaments et progrès thérapeutique: garantir l’accès, maîtriser les prix,
Propositions d’amendements au PLFSS pour 2019,
CSA survey for France Assos Santé: the French want a stronger and more protective Europe in the health field, May 2019

HEALTH ACTION INTERNATIONAL (HAI)
Clinical Trial Transparency at European Universities: Mapping unreported drug trials
HAI European Projects Guide 2019
Clinical Trials in the European Union: A Roadmap to Greater Transparency
TRIPS Flexibilities and Access to Medicines
New and Affordable Medicines in the Netherlands: Tracing the Dutch Government’s Policy Commitments and Actions
Guidelines for Socially Responsible Management of Innovation: Making research findings accessible and usable for as many people as possible
Fact or Fiction: What healthcare professionals need to know about pharmaceutical marketing in the European Union
Key recommendations on Health Technology Assessments
https://haiweb.org/publication/key-recommendations-on-health-technology-assessments/
MENTAL HEALTH EUROPE (MHE)

“Shedding Light” is a project run by Mental Health Europe, which looks at transparency issues between the mental health sector and the pharmaceutical industry. https://mhe-sme.org/shedding-light/

Medical education should be free from undue influence and conflicts of interest https://www.mhe-sme.org/medical-education-should-be-free-from-undue-influence-and-conflicts-of-interest/

PRAKSIS, GREECE

PRAKSISACCESS “watchdog” website: https://praksisaccess.org/
Campaign video: https://www.youtube.com/watch?v=9lKUX9qCS4&feature=youtu.be
Open research and medicines development call: https://praksisaccess.org/campaign/openpharma/
Q&A on affordable medicines concerning the situation in Greece: https://praksisaccess.org/faq/
On the issue with ROCHE HELLAS: https://praksisaccess.org/campaign/praksisioscotelic/
PRAKSIS 2017 Medical projects (access to medicines included): https://www.youtube.com/watch?v=m-dpoETW21M&feature=youtu.be&fbclid=IwAR0NYASUdYIdCy9-bqCZ9Agv06rgx3k3ie2cXgMVyPCJiXANEgiJEFLM
PRAKSIS 2016 Conference on affordability and access to medicines: https://www.youtube.com/watch?v=mQdBT1MBFunnmmr26sfg

ROMANIAN HEALTH OBSERVATORY

The crisis of anti-tuberculosis medicines in Romania, https://www.youtube.com/channel/UCX0Qd1BT1MBFunnmmr26sfg
Financial relationships between the pharma & medtech industry and the Romanian medical system in 2016, https://goo.gl/AzSmYH

WEMOS

Resources: http://www.wemosresources.org/search/?__sft_category=medicines
The long arm of the pharmaceutical industry, https://www.wemos.nl/en/the-long-arm-of-the-pharmaceutical-industry/
Infographic: The system of medicine development. What the EU and the Netherlands can do about it: http://www.wemosresources.org/access-to-medicines/the-system-of-medicine-development/?__sft_category=access-to-medicines
MEDICINES SHORTAGES: KEY RESOURCES

EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS (EAHP)

EAHP’s 2018 Survey on Medicines Shortages to improve patient outcomes,


EUROPEAN PUBLIC HEALTH ALLIANCE (EPHA)

EPHA joins calls for investigation into EU medicines shortages
https://epha.org/epha-joins-calls-for-investigation-into-eu-medicines-shortages/

EPHA joins calls for urgent European Parliament action on medicines shortages
https://epha.org/epha-joins-calls-for-urgent-european-parliament-action-on-medicines-shortages/

ROMANIAN HEALTH OBSERVATORY

Abstracts in English: Cancer Drugs Shortages in Romania - Magnitude, Causes and Solutions
https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3121/98149

Magnitude of Cancer Drugs Parallel Trade from Romania to European Union Countries in 2017
https://www.valueinhealthjournal.com/article/S1098-3015(19)30924-6/abstract

In extenso Reports in Romanian: Cancer Drugs Crisis in Romania: Causes & Solutions
https://drive.google.com/file/d/1-xv_Vkg7oODE8EHjtdoYf5aXyAecelp/view

Mapping Parallel Trade from Romania: Focus on Oncology
https://drive.google.com/file/d/1zz4Gty1OAbYFoY9gigl2YVzpyZ95I8jCP/view

FRANCE ASSOS SANTÉ

Survey on shortages of medicines and vaccines in France, December 2018 (in French)

Press-release on the measures proposed by the French government to fight medicines shortages, September 2019 (in French)
UNIVERSAL ACCESS AND AFFORDABLE MEDICINES FORUM

14 November 2019
Scotland House, Brussels

#newdeal4meds